Stopping Alzheimer’s Before It Starts: What The Lancet Says About the Future of Prevention
A new 2026 editorial in The Lancet Neurology makes something unmistakably clear:
"Alzheimer’s disease begins decades before symptoms appear."
Amyloid plaque accumulation, tau tangles, and neurodegeneration can silently progress for years—sometimes decades—before memory problems emerge. That silent window may be the most important opportunity we have. The critical question is no longer “Can we treat Alzheimer’s?” It’s becoming: “Can we stop it before symptoms begin?”
The Drug-First Prevention Model
Currently, the FDA has approved two anti-amyloid drugs—lecanemab and donanemab—for people with mild Alzheimer’s disease. The debate now centers on whether these drugs might work even better earlier, in cognitively normal individuals who already show biological markers of Alzheimer’s pathology. This approach depends on a key shift in how Alzheimer’s is defined.
The Alzheimer’s Association (AA) Workgroup defines Alzheimer’s biologically—based on biomarkers such as:
- Amyloid PET imaging
- Cerebrospinal fluid amyloid or tau
- Blood-based biomarkers
Under this framework, someone can be labeled as having Alzheimer’s disease before any cognitive symptoms appear.
If this biological definition becomes dominant, prevention would focus on identifying biomarker-positive individuals and treating them pharmacologically to halt disease progression.
As with most drug-first approach to health, this model is more controversial.
The Person-Centered Prevention Model
The International Working Group (IWG) offers a different perspective. One that aligns more with our mission here at Preventing Decline.
The IWG argue Alzheimer’s is a clinical-biological construct—meaning biomarkers alone are not sufficient to define the disease in someone without symptoms. Importantly, some individuals die at advanced ages with amyloid and tau pathology but never develop cognitive impairment. This suggests biomarkers may indicate risk—not inevitable disease.
Under the IWG model, cognitively healthy individuals with positive biomarkers are considered at risk, not already diseased. This distinction changes everything.
Instead of immediate drug therapy, prevention would prioritize:
- Cardiovascular risk reduction
- Physical activity
- Metabolic optimization
- Cognitive engagement
- Social connection
- Multi-domain lifestyle interventions
In Europe, this framework has led to recommendations for dedicated brain health services that evaluate risk and implement personalized prevention programs.
Why This Matters for Preventing Decline Members
The Lancet editorial ultimately argues that before prevention can accelerate, the field needs a unified definition of Alzheimer’s disease,
But here’s what is already clear:
- The disease process begins long before symptoms arise.
- There is a measurable preclinical window.
- Risk modification during this window matters.
At Preventing Decline, our model aligns strongly with the person-centered, multi-domain prevention approach.
While pharmacologic prevention remains under investigation, the lifestyle risk factors associated with dementia are already well established. Blood pressure, insulin resistance, physical inactivity, smoking, sleep quality, and social isolation are not theoretical risks—they are modifiable drivers of cognitive decline.
Even if anti-amyloid therapies eventually prove safe and effective in asymptomatic individuals, they will not replace foundational risk reduction. Biology is influenced by one’s everyday behavior.
The Strategic Takeaway
The future of Alzheimer’s prevention will likely involve two parallel tracks:
- Biological early detection
- Aggressive risk factor modification
But only one of those is available to you today.
You cannot yet access preventive anti-amyloid therapy as a cognitively normal adult.
You can optimize your metabolic health, increase your movement, improve your sleep, mental health, and social engagement immediately… with the right tools
The silent decades before symptoms appear are not passive years. They are intervention years.
The Lancet’s message is urgent:
If we want to stop Alzheimer’s, we must act before it announces itself.
At Preventing Decline, that action starts now.
What You Can Do Now - Take Action Before Symptoms Start
Step 1: Know Your Brain Care Score
If Alzheimer’s begins long before symptoms, then prevention must begin long before symptoms.
The Brain Care Score provides a measurable way to assess and improve the factors that influence cognitive resilience, including:
- Blood pressure
- Physical activity
- Nutrition quality
- Sleep habits
- Mental health
- Social engagement
- Metabolic health
You cannot improve what you do not measure.
Your Brain Care Score is not a diagnosis. It is a strategic dashboard. It shows you where risk is accumulating — and where intervention can begin today.
Start by identifying one domain you can improve this month. Small, consistent upgrades compound over years.
Step 2: Don’t Do It Alone — Join PD+
Prevention is not a one-time decision. It is a long-term strategy.
As a PD+ member, you gain:
- Structured, evidence-based guidance aligned with the latest research
- Monthly group coaching focused on actionable risk reduction
- Ongoing accountability and support
- Direct application of the Brain Care Score framework
- A community of individuals committed to protecting their cognitive future
The future of Alzheimer’s prevention may eventually include early pharmacologic therapies. But lifestyle-driven risk reduction is available now.
The most powerful intervention is not waiting on FDA approval.
It is the daily behaviors you choose.
If you are serious about protecting your brain before symptoms ever appear, calculate your Brain Care Score and become a PD+ member today.
Prevention is not passive.
It is proactive.
And it starts now.